COVID-19 patients frequently develop interleukin-6 (IL-6)-driven cytokine release syndrome (CRS), and elevated serum IL-6 correlates with respiratory failure and poor clinical outcomes [37]. This evidence concerns the gene IL6 and COVID-19.